Share Name Share Symbol Market Type Share ISIN Share Description
Reliance Gen. LSE:GMX London Ordinary Share GB00B1MM9925 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 0.55p 0.00p 0.00p - - - 0.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.5 -2.5 -0.9 - 0.86

Reliance Genemedix (GMX) Latest News

Real-Time news about Reliance Gen. (London Stock Exchange): 0 recent articles
More Reliance Genemedix News
Reliance Genemedix Takeover Rumours

Reliance Genemedix (GMX) Share Charts

1 Year Reliance Genemedix Chart

1 Year Reliance Genemedix Chart

1 Month Reliance Genemedix Chart

1 Month Reliance Genemedix Chart

Intraday Reliance Genemedix Chart

Intraday Reliance Genemedix Chart

Reliance Genemedix (GMX) Discussions and Chat

Reliance Genemedix Forums and Chat

Date Time Title Posts
07/3/201209:52And the most overvalued stock on the market is ?35.00
07/3/201209:51GMX- bid or merger344.00
03/2/201020:55GMX with Charts8.00
01/6/200710:12I hold and if Directors are correct re. future funding then23.00
19/2/200413:57The future is bright122.00

Add a New Thread

Reliance Genemedix (GMX) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Reliance Genemedix trades in real-time

Reliance Genemedix (GMX) Top Chat Posts

DateSubject
25/7/2006
12:31
jotoha1: Why is this company cap'd @£14million, is it april 1st, on my calc the share price should be 1/2p...any thoughts?
05/3/2005
22:41
eriktherock: by my calculations( provided upon kind request) we are looking at a share price of 22p based on current standing. This is high risk of course.
26/4/2004
20:16
handycam: My Dear Amarone, I encourage you to believe in the fact that a lot of directors do, actually, tell lies. Goodness knows how they habitually get away with it, but there we are. Remember also that, just like Turbo Genset, this duff company started life on ofex ( and to ofex it should return) with a market cap of £11m, equivalent to c. 3.5 pence in today's share price. Since that listing they have achieved nothing, apart from pee away a shedload of cash in a similar fashion to Scoot and Bright Station. I also recall that the gentleman behind the float trousered a bucketload of money from this and other comapnies before they, too, took a very real caning. You should ask people who paid £2 for this stock and ask them two questions: 1. What on earth made them pick up the phone to part with their cash for GMX? and 2. How do they feel now? I bet none would average down. In fact, if they are moderately intelligent, they would cut and reverse their long position and quadruple their bet on a CFD bear. Yours etc., Steven Ps. The placing was not with institutions, more like with Singaporean punters giving the company one last throw of the dice (and all of whom ought to know better). As British people did woth Eurodis and Mayflower.
23/2/2004
21:43
amarone: Talks with MNC set ablaze demand for GeneMedix By SERENA NG 19.02.04 (SINGAPORE) The Singapore market's only pure biotechnology stock, GeneMedix plc, yesterday gave an inkling of the huge potential new developments that the pharmaceutical industry could bring when its shares shot up two-thirds in a single day on hopes of a merger with a US giant. GeneMedix's shares, which had already gained nearly 30 per cent on Tuesday to 56 cents, yesterday jumped to a two-year high of $1.12 in intraday trade before ending at 92 cents, up 36 cents or a hefty 64 per cent. Some 31.3 million of GeneMedix shares were traded yesterday. The two-day share surge boosted GeneMedix's market capitalisation to some $275 million, from just $130 million on Monday. Investor euphoria over the counter was attributable to a Monday announcement by the London and Singapore-listed drugmaker, which had revealed that a 'significant transaction' was being negotiated with an international pharmaceutical products company. Loss-making GeneMedix, which was responding to recent market speculation, also said the talks 'may or may not lead to a merger between the two companies', adding it had recently indicated it was looking to access the US markets. Last week, the UK-based biotech firm also announced that it is working with the Bank of New York to establish an American Depository Receipt Programme on Nasdaq. GeneMedix cited its interest in accessing the US capital markets, which it said have tremendous interest in the emerging field of biogenerics, or generic therapeutic products that are produced through modern biotechnology processes. While GeneMedix, which makes protein-based drugs, did not name the company it is in talks with, market players concluded that the potential partner was probably an American firm with a sizeable presence. Bloomberg News also quoted the group's chief financial officer Julian Attfield saying that the talks, though preliminary, are focused on forming a collaborative partnership rather than a takeover by a potential buyer. GeneMedix's London-listed shares, meanwhile, have also more than doubled since the start of this week. The company was listed in Singapore on Dec 1, 2000, one day after listing on London, and its initial public offering (IPO) shares had been priced at 90 pence or $2.22. The stock subsequently hit a high of $3.06 here in February 2001, while its record low of 31.5 cents was seen earlier this month on Feb 2. Amid yesterday's stunning share price surge, some market players in Singapore reacted with scepticism. Said one active trader: 'It's a ridiculous price, and my gut feeling is that it's all hyped up. I did not like the fact that the stock ran up for a few days and then the company made its announcement.' He added that the sharp run-up might lead the other party to pull out, especially if a share swap was being planned. But for other market watchers, the volatility of GeneMedix's shares was seen as a reflection of the high risk-to-reward factor of biotechnology stocks, as such companies tend to be mired in losses for years before getting a big break. GeneMedix reported a net loss of 4.8 million (S$15 million) for the nine months to August 2003, versus a net loss of 6.6 million a year ago.
23/2/2004
13:47
andyprice5569: Hi Nil Pd, 'Now I wonder what would happen if Singapore traders bought their shares here (for two thirds of the price) instead of locally. Seems like we will be moving toward parity soon.' What is 'parity'? Firstly, one has to find out what price GMX opened at on the Singapore stock exchange (the first day of trading); find out what the GMX UK share price was that day; find out what the exchange rates (£ and Singapore $) was on the day GMX opened in Singapore; find out what the exchange rate for the £ and Sing $ is today; find out the difference. Currency fluctuations between the £ and the Sing $ will have had an effect on the price of shares in the UK (you think cheap) compared to the price of shares in Singapore (where you think they are dearer). HTH - Regs, Andy
19/2/2004
13:38
baker man: GeneMedix PLC 19 February 2004 GENEMEDIX PLC Statement Re: Share Price Movement GeneMedix plc ('the Company'), the UK biopharmaceutical company with operations in Europe and Asia and with joint London and Singapore Stock Exchange listings, makes the following statement regarding its share price: The Company notes the significant increase in its share price following its announcement on 16 February 2004. The Company wishes to clarify the position in relation to the significant potential transaction referred to in that announcement and its current financial position and prospects. The potential transaction referred to in the announcement of 16 February 2004 is at an early stage of negotiation. For the avoidance of doubt, no outright cash offer for the Company has been proposed and the Directors do not believe that any such offer is being contemplated. The Company announces today that it intends to release its preliminary results for the 12 months ended 30 November 2003 on 26 February 2004. Since the announcement of its interim results for the nine months ended 31 August 2003, in which the Directors highlighted the Company's need to focus on preserving its cash balances, the Company has continued to operate on a cash flow negative basis. In that announcement, the Directors expressed confidence in receiving cash in-flows in the very short term to cover the Company's immediate cash requirements. At this point, although the Company has received some additional funding, the cash in-flows contemplated in that announcement have not yet been received. However, the Directors remain confident of securing additional cash in-flows in the near future. The Directors will keep the market informed of developments. 19th February 2004 ENQUIRIES: GeneMedix plc Tel: 01638 663 320 Julian Attfield, Chief Financial Officer Bankside Consultants Tel: 0207 444 4140 Michael Padley/Susan Scott Further copies of this announcement are available from the Group's head office - Rosalind Franklin House, Fordham Road, Newmarket, Suffolk, CB8 7XN
19/2/2004
10:12
baker man: This appears to be the reason for the lead in Asia http://business-times.asia1.com.sg/sub/premiumstory/0,4574,108497,00.html Talks with MNC set ablaze demand for GeneMedix February 19th By SERENA NG (SINGAPORE) The Singapore market's only pure biotechnology stock, GeneMedix plc, yesterday gave an inkling of the huge potential new developments that the pharmaceutical industry could bring when its shares shot up two-thirds in a single day on hopes of a merger with a US giant. GeneMedix's shares, which had already gained nearly 30 per cent on Tuesday to 56 cents, yesterday jumped to a two-year high of $1.12 in intraday trade before ending at 92 cents, up 36 cents or a hefty 64 per cent. Some 31.3 million of GeneMedix shares were traded yesterday. The two-day share surge boosted GeneMedix's market capitalisation to some $275 million, from just $130 million on Monday. Investor euphoria over the counter was attributable to a Monday announcement by the London and Singapore-listed drugmaker, which had revealed that a 'significant transaction' was being negotiated with an international pharmaceutical products company. Loss-making GeneMedix, which was responding to recent market speculation, also said the talks 'may or may not lead to a merger between the two companies', adding it had recently indicated it was looking to access the US markets. Last week, the UK-based biotech firm also announced that it is working with the Bank of New York to establish an American Depository Receipt Programme on Nasdaq. GeneMedix cited its interest in accessing the US capital markets, which it said have tremendous interest in the emerging field of biogenerics, or generic therapeutic products that are produced through modern biotechnology processes. While GeneMedix, which makes protein-based drugs, did not name the company it is in talks with, market players concluded that the potential partner was probably an American firm with a sizeable presence. Bloomberg News also quoted the group's chief financial officer Julian Attfield saying that the talks, though preliminary, are focused on forming a collaborative partnership rather than a takeover by a potential buyer. GeneMedix's London-listed shares, meanwhile, have also more than doubled since the start of this week. The company was listed in Singapore on Dec 1, 2000, one day after listing on London, and its initial public offering (IPO) shares had been priced at 90 pence or $2.22. The stock subsequently hit a high of $3.06 here in February 2001, while its record low of 31.5 cents was seen earlier this month on Feb 2. Amid yesterday's stunning share price surge, some market players in Singapore reacted with scepticism. Said one active trader: 'It's a ridiculous price, and my gut feeling is that it's all hyped up. I did not like the fact that the stock ran up for a few days and then the company made its announcement.' He added that the sharp run-up might lead the other party to pull out, especially if a share swap was being planned. But for other market watchers, the volatility of GeneMedix's shares was seen as a reflection of the high risk-to-reward factor of biotechnology stocks, as such companies tend to be mired in losses for years before getting a big break. GeneMedix reported a net loss of 4.8 million (S$15 million) for the nine months to August 2003, versus a net loss of 6.6 million a year ago. In 2002, a local biotechnology start-up, Rockeby Biomed, was turned away by the Singapore Exchange because of concerns that the company could not turn profitable within 12 months. Rockeby, which is managed by mainly Singaporeans, successfully listed in Australia at the end of 2003 after raising A$4 million (S$5.3 million) in an IPO at 20 Australian cents each. Its shares yesterday ended at 18.5 Australian cents
18/2/2004
16:23
nikesh2: whoeva says its goin down is nuts ever heard of a small company merging to a big company it is a blatent takeover if the statement said it woz in takeover talks the share price would hav bin flyin they hav not dun so yet but when they do the share price will rise further my guess is 30p short term
16/2/2004
12:59
baker man: techair - lol Looking at a possible figure to put on gmx share price, i would expect nothing less than 16.5p as this was the level at which they raised funds in November - The private investors who put the money up (& are part of their ongoing Penang operations)would not be happy at anything less.
09/2/2004
23:14
anakin54321: A quick glance at the shareprice history will reveal that the market recovery of the last 10 months or so has had no discernable impact on this share. Currently though it does appear to have stabilised at around the 9 pence mark (it rose significantly today on modest volume) which values GMX at around £27m. Anyone remotely interested should listen to the Wall Street Reporter interview with the CEO a few weeks ago ( www.wallstreetreporter.com/linked/GeneMedix.html ). It offers a really useful background and investment case (particularly in relation to the recent appointment of US Investment Bankers to provide access to the lucrative American market)and leaves you with the conclusion that the next 2 years could be transformational for this company. It could be argued that everything they've done to date has helped to prepare them for 2005/06 and that the historical shareprice is largely irrelevant. The CEO is certainly very bullish and is confident of licensing deals in the "next few months" from the US which will bring valuable cash to the bottom line. With the fourth quarter results due on the 26th of this month (according to the website) we could well see a gradual increase over the next couple of weeks in anticipation of more corporate developments.If GMX can make inroads into the US market than its potential will be rapidly realised. After all, it will only take a relatively modest share of a market valued in the tens of billions to transform the share price. All IMHO.
Reliance Genemedix share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20161206 12:08:03